# BI-1808

Source: https://onco.cc/drugs/bi-1808/  
OnCo record `bi-1808` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BI-1808 is an experimental monoclonal antibody from BioInvent International, in phase 2 trials for cutaneous T-cell lymphoma, T-cell lymphoma and ovarian cancer and other cancers.

## Summary

BI-1808 is a monoclonal antibody from BioInvent International. A first-in-class anti-TNFR2 antibody that is part of BioInvent's programme targeting tumour-associated regulatory T cells; tested alone and with pembrolizumab. Its furthest stage is phase 2, for cutaneous T-cell lymphoma, T-cell lymphoma, ovarian cancer and melanoma. ClinicalTrials.gov registers it in one study linked below. Phase 1/2a NCT04752826 recruiting (registry, checked 3 Nov 2026); updated phase 2a CTCL data presented at EHA 2026. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: BI-1808
- Modality: Monoclonal antibody
- Mechanism: A first-in-class anti-TNFR2 antibody that is part of BioInvent's programme targeting tumour-associated regulatory T cells; tested alone and with pembrolizumab.

## Sources

- BioInvent International: bioinvent.com: https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1808-t-cell-lymphoma
- BioInvent International: bioinvent.com: https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1808-t-cell-lymphoma
- ClinicalTrials.gov: trials of BI-1808: https://clinicaltrials.gov/search?intr=BI-1808

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [BioInvent International](https://onco.cc/companies/bioinvent-international/)
- trials: [BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)](https://onco.cc/trials/nct04752826/)

---
JSON: https://onco.cc/api/v1/entities/bi-1808.json